ReShape Lifesciences Inc represents the values of innovation, patient-centric approach, and commitment to improving the lives of individuals struggling with obesity and metabolic diseases. The company's corporate philosophy revolves around developing and delivering advanced solutions for weight loss and metabolic health management. With a strong focus on research and development, ReShape Lifesciences strives to provide effective and minimally invasive medical devices that offer long-term solutions for patients. By continuously evolving and advancing their technologies, the company aims to empower individuals to achieve sustainable weight loss and lead healthier lives.

ReShape Lifesciences Inc is primarily present in the United States.

ReShape Lifesciences Inc has achieved significant milestones in its growth as a medical device company. Some notable achievements include the development and FDA clearance of the ReShape Duo, a non-surgical weight loss solution. The company has also successfully expanded its commercial footprint and established partnerships with healthcare providers. ReShape Lifesciences Inc has demonstrated its commitment to innovation by securing a number of patents for its products. Additionally, the company has made strategic acquisitions, such as acquiring the Lap-Band gastric banding system, which has further strengthened its position in the weight loss market.

ReShape Lifesciences Inc, formerly known as EnteroMedics Inc, is a medical device company focused on the development and commercialization of innovative technologies to treat obesity and other metabolic diseases. The company's primary product, the ReShape Vest System, is an FDA-approved non-surgical weight loss solution that uses dual balloons to occupy space within the stomach, promoting feelings of fullness and reducing food intake. ReShape Lifesciences Inc was founded in 2002 and is headquartered in San Clemente, California. With a strong commitment to addressing the global obesity epidemic, the company continues to research and develop new medical devices to improve patient outcomes in the field of metabolic health.

The main competitors of ReShape Lifesciences Inc in the market are Medtronic plc, Apollo Endosurgery Inc, and EnteroMedics Inc.

ReShape Lifesciences Inc is primarily active in the medical devices and healthcare industries.

The business model of ReShape Lifesciences Inc is centered around providing innovative medical devices and therapies for weight loss and obesity management. The company focuses on developing and commercializing minimally invasive solutions that can help individuals achieve their weight loss goals effectively and safely. With a strong emphasis on medical technology, ReShape Lifesciences Inc aims to improve the quality of life for patients struggling with obesity through devices like the ReShape Balloon System. Through its advanced products and commitment to patient care, ReShape Lifesciences Inc seeks to address the global health challenge of obesity effectively.

P/E odnos ReShape Lifesciences iznosi -2,30.

KUV kompanije ReShape Lifesciences iznosi 0,05.

AlleAktien kvalitativni skor za ReShape Lifesciences je 4/10.

očekivana ReShape Lifesciences promet je 10,19 mil. USD.

Dobit očekivana ReShape Lifesciences je -234.089,99 USD.

ReShape Lifesciences Inc is a leading company in the field of medical innovations and follows a business model based on the development, manufacturing, and marketing of medical devices and technologies. The company operates in various areas, including the treatment of obesity, gastrointestinal diseases, and metabolic disorders. One of the company's main divisions is the treatment of obesity and associated comorbidities. Here, the company offers innovative solutions that aim to promote weight loss and minimize the risk of complications. Products in this area include gastric bands, gastric balloons, and other endoscopic procedures that help reduce the size of the stomach and reduce appetite. Another area in which the company operates is the treatment of gastrointestinal diseases. ReShape Lifesciences Inc offers innovative technologies that aim to improve the lives of patients with chronic conditions such as Crohn's disease or ulcerative colitis. One of their key technologies in this area is the Hydro-Sponge capsule, which can help alleviate the symptoms of these diseases. Another important area in which the company operates is the treatment of metabolic disorders. Here, ReShape Lifesciences Inc offers innovative solutions that aim to regulate blood sugar levels and minimize the risk of complications in diabetes. Products in this area include insulin syringes, insulin pumps, and other devices that help optimize therapy and reduce insulin requirements. Overall, ReShape Lifesciences Inc follows a business model based on the development, manufacturing, and marketing of medical devices and technologies that aim to improve people's lives and treat diseases. Through close collaboration with doctors, clinics, and other medical facilities, the company is able to constantly improve its products and meet the needs of patients. To successfully implement its business model, ReShape Lifesciences Inc focuses on strong customer orientation, close collaboration with partners, and continuous innovation. The company strives to offer its customers high-quality products that are state-of-the-art and meet the needs of patients. In summary, ReShape Lifesciences Inc is a leading company in the field of medical innovations that offers a wide range of products and technologies for the treatment of obesity, gastrointestinal diseases, and metabolic disorders. Through strong customer orientation and close collaboration with doctors and clinics, the company is able to offer its customers high-quality and innovative solutions aimed at improving people's lives and treating diseases.

ReShape Lifesciences isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za ReShape Lifesciences trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od ReShape Lifesciences je US7611236032.

Oznaka za praćenje akcija kompanije ReShape Lifesciences je RSLS.

U poslednjih 12 meseci, ReShape Lifesciences je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, ReShape Lifesciences će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od ReShape Lifesciences trenutno iznosi .

ReShape Lifesciences isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

ReShape Lifesciences je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

ReShape Lifesciences se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od ReShape Lifesciences od 17. 11. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 17. 11. 2024..

Isplata poslednje dividende izvršena je 17. 11. 2024..

U godini 2023 kompanija ReShape Lifesciences je isplatila 0 USD kao dividende.

Dividende od ReShape Lifesciences se isplaćuju u USD.